Evidence of disulfide bond scrambling during production of an antibody-drug conjugate

Abstract

Antibody-drug conjugates (ADCs) that are formed using thiol-maleimide chemistry are commonly produced by reactions that occur at or above neutral pHs. Alkaline environments can promote disulfide bond scrambling, and may result in the reconfiguration of interchain disulfide bonds in IgG antibodies, particularly in the IgG2 and IgG4 subclasses. IgG2-A and IgG2-B antibodies generated under basic conditions yielded ADCs with comparable average drug-to-antibody ratios and conjugate distributions. In contrast, the antibody disulfide configuration affected the distribution of ADCs generated under acidic conditions. The similarities of the ADCs derived from alkaline reactions were attributed to the scrambling of interchain disulfide bonds during the partial reduction step, where conversion of the IgG2-A isoform to the IgG2-B isoform was favored. ARTICLE HISTORY

Current advances in biopharmaceutical informatics: guidelines, impact and challenges in the computational developability assessment of antibody therapeutics

“… 80 , 81 Disulfide scrambling due to cysteine residues is another phenomenon causing configurational changes in the hinge region of antibodies, thus impeding antigen binding and mAb functionalities. 82 , 83 The variable domains of mAbs may also contain N-glycosylation sites, which may cause variable domain glycosylation that results in the formation of Fab-associated oligosaccharides with α1,3-galactose that are known to cause immunogenicity. 84–86 These PTMs often lead to low potency, immunogenicity, and instability of circulating mAbs.…”

Systematic identification of engineered methionines and oxaziridines for efficient, stable, and site-specific antibody bioconjugation

“…Cysteine is becoming more commonly used as it is far less abundant than lysine and affords greater site-selectivity. However, this approach usually involves random reduction of the interchain disulfide bonds of the antibody that can still lead to heterogeneous mixtures (14,19,20). Recently, researchers have systematically introduced single cysteine residues into the therapeutic antibody, trastuzumab, to identify sites for stable and specific conjugation (21,22).…”

Sensitive Immunofluorescent Detection of the PRAME Antigen Using a Practical Antibody Conjugation Approach

“…For example, modification of lysine side chain NH 2 groups does not provide regiospecificity, thus, excessive labeling of an antibody diminishes its affinity [ 2 , 3 , 6 ]. Partial reduction of disulfide bridges, followed by Michael-type modification of any arising thiol groups, may cause disulfide bond scrambling and break the native quaternary antibody structure [ 13 , 14 , 15 ]. In addition, there are many complex chemical and chemo-enzymatic techniques for site-specific antibody modification using intricate modification reagents [ 12 , 16 , 17 , 18 , 19 , 20 ].…”